Cold virus turned cancer killer: new hope for liver cancer patients?
NCT ID NCT05733598
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a genetically modified herpes virus (RP2) that infects and destroys cancer cells while also stimulating the immune system. It is given alone or together with standard drugs (bevacizumab, atezolizumab, or durvalumab) to 60 adults with advanced liver or bile duct cancer that has worsened after initial treatment. The goal is to see if the combination shrinks tumors and how safe it is.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RP2 (a modified herpes virus that attacks tumors and boosts the immune system), given alone or with bevacizumab, atezolizumab, or durvalumab
What this could lead to
If successful, this could offer a new second-line treatment option for people with advanced liver or bile duct cancer that has not responded to initial therapy.
What could go wrong
This is an early phase 2 trial with only 60 participants, so results may not apply broadly. The virus-based therapy can cause flu-like symptoms, injection site reactions, and other immune-related side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beverly Hills Cancer Center
RECRUITINGBeverly Hills, California, 90211, United States
Contact
-
Houston Methodist Hospital Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
-
Montefiore Medical CenterMontefiore Medical Park
RECRUITINGThe Bronx, New York, 10461, United States
Contact
-
Roswell Park Comprehensive Cancer Center
RECRUITINGBuffalo, New York, 14236, United States
Contact
-
Sylvester Comprehensive Cancer Center (University of Miami Hospital and Clinics)
RECRUITINGMiami, Florida, 33136, United States
Contact
-
The West Clinic
RECRUITINGGermantown, Tennessee, 38138, United States
Contact
-
UC San Diego Moores Cancer Center
RECRUITINGLa Jolla, California, 92037, United States
Contact
-
UPMC Hillman Cancer Center
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact
-
University of Maryland Medical Center
RECRUITINGBaltimore, Maryland, 21201, United States
Contact
-
University of Pennsylvania, Abramson Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact
-
University of Tennessee Medical Center
RECRUITINGKnoxville, Tennessee, 37920, United States
Contact